Dr. Frédéric Fiore is a recognized expert in preclinical genetic engineering and transgenesis, with more than three decades of experience in the development of advanced murine models for biomedical research. He began his career in 1993 under the mentorship of Dr. Daniel Birnbaum at the Marseille Cancer Research Center, where he contributed to the creation of the first knockout and knock-in mouse models in France. Dr. Fiore earned his PhD in Eukaryotic Biology (Genetic and Developmental Aspects) in 2002 from the Université de la Méditerranée, Faculty of Sciences of Luminy (Marseille, France). In 2007, Dr. Fiore joined Dr. Bernard Malissen at the Centre d’Immunologie de Marseille-Luminy (CIML), where he directed the IBiSA-accredited KOKI-Booster platform and played a pivotal role in the Fondation of the Centre d’ImmunoPHEnomique (CIPHE). Since 2012, he has led the Genetic Engineering and Mouse Transgenesis (GEMTis) platform within CIPHE, where he currently serves as Chief Scientific Officer (CSO). Throughout his career, Dr. Fiore has supervised the design, implementation, and management of over 700 mouse models and several rat models, serving more than 80 academic, biotech, and pharmaceutical laboratories worldwide. His leadership has been instrumental in implementing cutting-edge technologies, ensuring rigorous risk management, and expanding the platform’s capabilities to include new methodologies. Alongside his scientific leadership, he contributes actively to training and education, teaching genetic engineering in several Master’s programs and participating in institutional and regulatory continuing education initiatives. He has been deeply involved in national and international networks in mouse genomics and model development, including PHENOMIN/CELPHEDIA, INFRAFRONTIER, KOMP/IMPC, and the International Society for Transgenic Technologies (ISTT). Between 2010 and 2015, he coordinated the French national network ROCAD, integrating it into CELPHEDIA in 2016, and previously led Work Package 8: “New Transgenesis Techniques and ES Cells” within this framework. His contributions to preclinical research are reflected in numerous high-impact publications, including recent collaborative studies published in Nature Immunology (2025), Oncoimmunology (2025), Journal of Experimental Medicine (2025), JHEP Reports (2025), and EMBO Reports (2024). In addition to his academic and institutional responsibilities, Dr. Fiore is the founder of JCD Discovery (2022), spin off of CIPHE-INSERM and Janvier Lab Group, a biotechnology initiative dedicated to advancing and supporting translational research and drug discovery. Dr. Fiore’s achievements have been recognized through several distinctions, notably the Inserm Innovation Award (2011) and his selection for Inserm’s High-Potential Leadership Program (2016–2017). His career is characterized by a consistent commitment the advancement of genetic engineering methodologies, innovation, and collaboration in support of biomedical discovery. frederic.fiore@inserm.fr / ORCID ID: 0000-0001-7955-6594

Dr Hervé Luche is an expert in T-cell and myeloid immunology, high-content cytometry, and single-cell transcriptomics (scRNAseq). He obtained his PhD in Developmental Immunology at the Medical University of Ulm, Germany, in the laboratory of Hans-Joerg Fehling, and carried out postdoctoral studies at the CIML, Marseille, in the laboratory of Bernard and Marie Malissen, where he engineered knock-in mouse strains to study lineage commitment and T-cell differentiation. Since 2012, Dr Luche has been a key scientist at the Centre d’ImmunoPHEnomics (CIPHE), where he directs the Immuno-Phenotyping Module. His team develops standardized methodologies, multi-parametric flow, mass, and spectral cytometry panels, and functional assays to establish immune system status in basal, inflammatory, oncology, and infectious contexts in mice. These standardized approaches enable robust immunophenotyping across preclinical studies and translational research projects. Dr Luche contributes to national and international phenotyping initiatives, including the International Mouse Phenotyping Consortium (IMPC), and has been leading a team of 5 engineers since 2018. His group focuses on immune profiling, T-cell differentiation, dendritic cell biology, and integrative single-cell analyses, providing mechanistic insights into immunopathology, tumor immunology, and host-pathogen interactions. As a PI, Dr Luche has obtained multiple competitive grants from ANR, INCA, SFB, and European funding programs, supporting projects ranging from high-dimensional immune profiling to translational immunotherapy studies. He actively participates in scientific training, organizes workshops, and contributes to the development of new analysis pipelines for multi-modal cytometry and scRNAseq data. Dr Luche has authored over 50 peer-reviewed publications, including in Science, Immunity, EMBO Journal, Frontiers in Immunology, and has contributed to key methodological advances in flow and mass cytometry, lineage tracing, and single-cell immune profiling. His work combines cutting-edge immunomics with robust preclinical modeling to improve translational predictions for immune-based therapeutics. In addition to his research, Dr Luche is a scientific advisor and co-founder of JC Discovery, mentoring the next generation of immunologists and fostering collaborations between academia and industry. He is recognized for his expertise in high-dimensional cytometry, T-cell and dendritic cell biology, and immune system modeling, positioning CIPHE as a leading platform for preclinical immune phenotyping in Europe. herve.luche@inserm.fr

Dr. Ana Zarubica is the Director of the Centre d’Immunophénomique (CIPHE), a leading academic service, research, and technology unit specializing in mouse genetics, immunology, and preclinical modeling. Founded in 2011 by Dr. Bernard Malissen, CIPHE integrates technological platforms to support the design, generation, and functional analysis of rodent models, focusing on inflammation, infection, and cancer. Dr. Zarubica provides strategic and scientific leadership, oversees the development of new technologies, and cultivates collaborations with both academic and industrial partners to advance translational research. Dr. Zarubica earned her PhD in Immunology from Aix-Marseille University (2009), training at the Centre d’Immunologie de Marseille-Luminy (CIML) under Dr. Giovanna Chimini via the European ESR-RTN Marie Curie program. She completed postdoctoral research at the Centre de Recherche en Cancérologie de Marseille (CRCM) with Dr. Michel Aurrand-Lions, studying leuko-stromal interactions in hematopoiesis. She also received training in administrative and financial functions at INSERM PACA, reflecting her expertise in leading complex research infrastructures. Since March 2020, Dr. Zarubica has directed CIPHE’s contributions to preclinical modeling of emerging respiratory infections, including SARS-CoV-2. Leveraging the center’s BSL-3/BSL-2 infrastructure and genetic engineering and immunology expertise of CIPHE teams, knock-in mouse models expressing human ACE2 (hACE2) have been developped, enabling in-depth analyses of viral pathogenesis, immune responses, and the lung-brain axis in COVID-19. These models have been critical for testing antivirals, monoclonal antibodies, vaccines, and anti-inflammatory therapies in preclinical settings. CIPHE’s teams are currently establishing advanced technological platforms for plethysmography, nebulization, and behavioral studies, integrated organoid models, and contributing to many collaborative projects with national and international partners, including JAX Laboratory, KOMP, Institut Pasteur, VRI, and VirPath Lyon. Dr. Zarubica has secured multiple competitive grants supporting translational and preclinical research, since 2020. The work of CIPHE’s team has yielded publications in Nature Communications, Communications Biology, Advanced Science, EBioMedicine, Frontiers in Cellular and Infection Microbiology, and Immunity, covering antiviral therapeutics, host-pathogen interactions, and mucosal immunology. Dr. Zarubica has been awarded the INSERM Prize “Appui à la Recherche” (2021) and recognized in Inserm and AMU High-Potential Leadership Programs (2018–2020, 2025–2026). Beyond research, Dr. Zarubica actively contributes to immunology curriculum and training programs, and participates in national and international committees and consortia, including IBiSA, PHENOMIN, CELPHEDIA, ANRS-MIE, ERIC INFRAFRONTIER. She is a scientific advisor and co-founder of JC Discovery  ,a spin-off bridging CIPHE’s academic expertise with translational applications in therapeutic development. ana.zarubica@inserm.fr / ORCID ID: 0000-0001-5488-4137

Amandine Sansoni has over 20 years of experience in mouse model experimentation, including colony management, surgery, infectious models, genotyping, and phenotyping.  She leads all operational aspects of the platform, including cryopreservation rederivation and cohort production , ensuring high-quality and reproducible models for preclinical research.  Her team supports disease modeling projects in immunology, neurology, and infectious diseases.  As Animal Welfare Officer (SBEA), she promotes best practices and the 3Rs principles (Replacement, Reduction, Refinement). Amandine is also a certified trainer in regulatory animal experimentation courses and advises researchers on ethical, scientifically sound protocols.  She is deeply involved in collaborative projects requiring long-term colony management and complex breeding strategies. amandine.sansoni@inserm.fr